Lisa Crocker
ScholarGPS® ID: 78738004248589
Affiliation History
Field
Medicine
Discipline
Oncology
Top Specialties
Cancer | Breast Cancer
Metrics Summary
Publication Count
20
Predicted Citations
4,620
Predicted h-index
18
Ranking
Publications and Citation History
Publications based on Top Specialties
Types of Publication
- Publications
- Books
- Patents
- NIH/NSF
Add
Delete
|
---|
Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action (journal article) Journal of Biological Chemistry, volume 299, issue 1, pages 102729- (2023). |
Cancer Research, volume 80, issue 11, pages 2368-2379 (2020). |
NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma (journal article) eLife, volume 8 (2019). |
Molecular Cancer Therapeutics, volume 17, issue 7, pages 1441-1453 (2018). |
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer (journal article) Molecular Cancer Therapeutics, volume 17, issue 3, pages 638-649 (2018). |
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer (journal article) Clinical Cancer Research, volume 23, issue 18, pages 5561-5572 (2017). |
An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies (journal article) Clinical Cancer Research, volume 21, issue 14, pages 3252-3262 (2015). |
An Anti-B7-H4 Antibody–Drug Conjugate for the Treatment of Breast Cancer (journal article) Molecular Pharmaceutics, volume 12, issue 6, pages 1717-1729 (2015). |
Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors (journal article) PLoS ONE, volume 9, issue 10, pages e109366- (2014). |
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition (journal article) Genes & Cancer, volume 5, issue 3-4, pages 113-126 (2014). |
Clinical Cancer Research, volume 20, issue 2, pages 456-468 (2014). |
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose (journal article) Cancer Chemotherapy and Pharmacology, volume 69, issue 4, pages 1063-1069 (2012). |
A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies (journal article) Cancer Cell, volume 20, issue 4, pages 472-486 (2011). |
Journal of Pharmacokinetics and Pharmacodynamics, volume 37, issue 3, pages 221-242 (2010). |
Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer (journal article) Cancer Research, volume 70, issue 11, pages 4481-4489 (2010). |
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate (journal article) Cancer Research, volume 68, issue 22, pages 9280-9290 (2008). |
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy (journal article) Cancer Research, volume 68, issue 14, pages 5878-5887 (2008). |
Patent Number: 20090098115 (2007) |
Patent Number: 20060212956 (2006) |
The FASEB Journal, volume 20, issue 5 (2006). |